Heart device tested in Real-World AF patients
NCT ID NCT05434650
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 200 people with persistent atrial fibrillation (AF) who undergo a heart procedure using Abbott's ablation catheter. The catheter uses heat to scar tiny areas in the heart and block faulty electrical signals. Researchers track how many patients stay free of AF for up to 3 years, and check for serious side effects within a week of the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abbott Ablation Catheter (TactiCath SE) delivering radiofrequency energy
What this could lead to
If successful, this could confirm that the ablation device is a safe and effective long-term option for controlling atrial fibrillation without needing lifelong medication.
What could go wrong
This is a post-approval study, not a new breakthrough. The procedure carries risks like heart damage, stroke, or bleeding. Success depends on patient selection and real-world conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL TACHYCARDIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arkansas Cardiology
Little Rock, Arkansas, 72205, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham & Women's Hospital
Boston, Massachusetts, 02115, United States
-
Centennial Medical Center
Nashville, Tennessee, 37203, United States
-
Chippenham Hospital
Richmond, Virginia, 23225, United States
-
Doylestown Hospital
Doylestown, Pennsylvania, 18901, United States
-
Eisenhower Medical Center
Rancho Mirage, California, 92270, United States
-
Erlanger Medical Center
Chattanooga, Tennessee, 37403, United States
-
Heart Center Research, LLC.
Huntsville, Alabama, 35801, United States
-
Methodist Hospital of San Antonio
San Antonio, Texas, 78229, United States
-
North Mississippi Medical Center
Tupelo, Mississippi, 38801, United States
-
Northside Hospital
Atlanta, Georgia, 30342, United States
-
Ochsner Medical Center
New Orleans, Louisiana, 70121, United States
-
Oklahoma Heart Hospital South
Oklahoma City, Oklahoma, 73135, United States
-
Providence Hospital
Southfield, Michigan, 48075, United States
-
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507, United States
-
Sequoia Hospital
Redwood City, California, 94062, United States
-
St. Marks Hospital
Salt Lake City, Utah, 84124, United States
-
St. Patrick Hospital
Missoula, Montana, 59802, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States